Only a small proportion of people with a substance use disorder (SUD) receive treatment.
The shortage of SUD treatment providers, particularly in rural areas, is an important driver of …

Since the United States COVID-19 pandemic emergency began, telemedicine use has
accelerated [1]. Prior to the pandemic, mental health and/or substance use disorder …

Objectives: To retrospectively review clinic records to assess the difference between face-to-
face and telepsychiatry buprenorphine medication-assisted treatment (MAT) programs for …

Telemedicine is increasingly being used to treat patients with opioid use disorder (OUD). It
has particular value in rural areas of the United States impacted by the opioid crisis as these …

Objectives The COVID-19 pandemic led to the closure of the IDEA syringe services program
medical student-run free clinic in Miami, Florida. In an effort to continue to serve the …

Telemedicine could improve access to medications for opioid use disorder (MOUD).
Telemedicine-delivered MOUD (TMOUD) has expanded substantially in response to the …

Background Buprenorphine-naloxone is an evidence-based treatment for opioid use
disorder (OUD). Despite its efficacy, nearly half of patients discontinue treatment …

During the COVID-19 pandemic, many addiction treatment and harm reduction
organizations have had to reduce their hours and services for people with substance use …

Abstract Background The Ryan Haight Act generally requires a clinician to conduct an in-
person visit before prescribing an opioid use disorder (OUD) medication. This requirement …

With increased negative impacts from opioid and other substance use disorders in the US, it
is important for treatments to not only be effective, but also accessible to patients. Treatment …